{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.40","upperLimit":"10.38","value":"6.90"},{"groupId":"OG001","lowerLimit":"2.10","upperLimit":"12.71","value":"5.49"},{"groupId":"OG002","lowerLimit":"4.24","upperLimit":"10.38","value":"7.46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"Time from first response to progression based on investigator assessment. See definitions of response and progression in ORR and PFS outcomes.","dispersionType":"95% Confidence Interval","groups":[{"description":"Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.\n\nMelphalan flufenamide (Melflufen)\n\nDexamethasone: IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.","id":"OG000","title":"Melphalan Flufenamide (Melflufen) + Dexamethasone: Full Analysis Set"},{"description":"Patients with extramedullary disease at baseline defined as myeloma disease either originating in, but extending beyond, the cortical bone or as a separate soft tissue mass","id":"OG001","title":"Melphalan Flufenamide (Melflufen) + Dexamethasone: Patients With Extramedullary Disease"},{"description":"Triple class refractory population defined as refractory to or intolerant of at least one immunomodulatory drug, at least one proteasome inhibitor, and at least one anti-CD38 monoclonal antibody","id":"OG002","title":"Melphalan Flufenamide (Melflufen) + Dexamethasone: Patients With Triple Class Refractory Disease"}],"paramType":"MEDIAN","populationDescription":"Patients with a best response of PR or better as determined by the investigator.","reportingStatus":"POSTED","timeFrame":"From date of response until the date of first documented progression or date of death from any cause, whichever came first. Longest time of response recorded as 36.2 months at study end.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}